Thymosin Alpha 1 · Research brief

How Much Does Thymosin Alpha 1 Cost? Research Pricing

Real Peptides Research TeamEditorial

Updated September 24, 202610 min read

59 WORDS

Short answer

A vial labelled 10mg rarely contains 10mg of thymosin alpha 1 . Lyophilised peptides carry residual water and a trifluoroacetate counterion left behind from purification, and that mass sits on the balance right alongside the molecule itself. Price per vial and price per milligram of real peptide are two completely different numbers, and almost nobody compares the second one.

Key takeaways

Research-grade thymosin alpha 1 typically runs roughly $40 to $150 per vial, while pharmaceutical thymalfasin in approved markets costs substantially more.
How much does thymosin alpha 1 cost depends more on documented peptide content and purity specification than on brand or presentation.
The label milligram figure is usually gross vial weight; trifluoroacetate salt and residual moisture mean net peptide is commonly lower.
Thymosin alpha 1 is a 28-amino-acid peptide that signals through TLR2 and TLR9 on dendritic cells, driving a Th1-polarised cytokine response rather than acting directly on pathogens.
Thymalfasin holds approval in several countries outside the United States but has no FDA approval, and US compounding access is restricted by the bulk-substance categorisation.
Plasma half-life is reported in hours, while immunological endpoints in published trials shift across weeks of repeated administration.

A vial labelled 10mg rarely contains 10mg of thymosin alpha 1. Lyophilised peptides carry residual water and a trifluoroacetate counterion left behind from purification, and that mass sits on the balance right alongside the molecule itself. Price per vial and price per milligram of real peptide are two completely different numbers, and almost nobody compares the second one.

We supply research-grade peptides to laboratories, and pricing is the question that lands in our inbox before any other. Our team has found the pattern to be consistent: the sticker figure tells you almost nothing until you know the purity specification, the documented peptide content, and which supply channel produced the vial.

How much does thymosin alpha 1 cost?

Research-grade thymosin alpha 1 typically costs roughly $40 to $150 per vial, depending on vial size (commonly 5mg or 10mg), documented purity, and order volume. Pharmaceutical thymalfasin, sold as Zadaxin in countries where it holds approval, typically costs substantially more per vial. Compare peptide content, not gross vial weight.

The common error is treating the cost of thymosin alpha 1 as a single figure. It isn't. So how much does thymosin alpha 1 cost? It depends entirely on which of three markets the vial came from, because a regulator-approved medicine, a documented research-use-only vial, and an anonymous marketplace listing are three different products with three different paper trails. What follows covers the immunological mechanism, the regulatory split that created the price gap, and the specific variables that move a research vial's price.

The 28-amino-acid molecule behind the immune research

Thymosin alpha 1 (also written Ta1, and known pharmaceutically as thymalfasin) is a 28-amino-acid, N-terminally acetylated peptide first isolated from thymosin fraction 5, a calf thymus extract characterised by Allan Goldstein and colleagues in the 1970s. In the body it's cleaved from a larger precursor protein, prothymosin alpha, and it's produced by thymic epithelial tissue.

How does thymosin alpha 1 work? The published immunology describes a signalling peptide, not a hormone replacement. Research suggests it binds Toll-like receptors, principally TLR2 and TLR9, on dendritic cells and monocytes, which pushes dendritic cell maturation and a Th1-polarised cytokine profile (interferon-gamma, IL-2, IL-12). Downstream, the literature reports effects on thymic T-cell maturation and natural killer cell activity. It doesn't attack pathogens directly. It modulates the cells that do.

What is thymosin alpha 1 used for in the research record? Published work has concentrated on chronic hepatitis B and C, vaccine adjuvant studies in older populations where age-related thymic involution blunts the immune response, sepsis and critical care (including the ETASS randomised trial conducted in China), and supportive oncology settings. Results across those areas are mixed, and the largest body of clinical evidence comes from jurisdictions outside the United States.

In our experience fielding technical questions from labs, the mechanism is what researchers ask about second. Purity documentation is what they ask about first, and they're right to.

What actually sets the price of a research vial

Ask how much does thymosin alpha 1 cost and the honest answer begins with synthesis chemistry, not with margin. At 28 residues, this peptide is built through solid-phase peptide synthesis, where every single residue requires its own coupling and deprotection cycle. Crude yield decays as the chain lengthens, so a 28-mer costs considerably more per milligram to produce than a tripeptide like GHK-Cu. The N-terminal acetylation adds another step. Reaching a 98% or higher purity specification then requires preparative reverse-phase HPLC, sometimes across multiple passes, followed by lyophilisation and quality control by analytical HPLC plus mass spectrometry for identity confirmation.

Here's the part most price comparisons miss entirely. The milligram figure on a peptide label is usually gross vial weight, not net peptide. Trifluoroacetate salt from HPLC purification plus residual moisture commonly account for a meaningful fraction of that mass, which is why a certificate of analysis that reports peptide content separately from net weight is worth more than a lower headline price. Two vials both stamped 10mg can differ materially in how much thymosin alpha 1 they actually contain, and only one of those suppliers told you.

The rest of the thymosin alpha 1 price is unglamorous logistics: batch size economics, third-party analytical testing, and cold-chain packaging. Our team has reviewed enough incoming batch data to say plainly that the suppliers cutting price hardest are almost always cutting the mass spectrometry step, because it's the line item a customer can't see.

Regulatory status is why the market splits in two

Thymalfasin is an approved medicine in a number of countries outside the United States, marketed under the brand name Zadaxin for indications including chronic hepatitis B. It has not been approved by the FDA for any indication in the US. That single regulatory fact creates the entire price structure discussed here.

The FDA's evaluation of bulk drug substances nominated for use in compounding placed thymosin alpha-1 in the category that significantly restricts compounding under section 503A, which effectively closed the compounding-pharmacy route domestically. What remains in the US is research-use-only material, and research-use-only means exactly what it says: in vitro and laboratory investigation, not human or veterinary consumption. Any researcher designing animal-model work should talk to their veterinarian about welfare, handling and institutional approval before a single vial is opened.

Is thymosin alpha 1 safe? Clinical literature from markets where thymalfasin is approved describes it as generally well tolerated, with injection-site reactions among the more commonly reported events. That safety record belongs to a sterile, endotoxin-tested pharmaceutical product manufactured under GMP conditions. It does not transfer to research-grade powder, which is not manufactured, tested or released as a sterile injectable drug product. Conflating the two is the single most common reasoning error we see in this category.

The information here is educational and describes what the research literature and regulatory record report. It is not administration guidance for any person or animal.

Handling, reconstitution arithmetic, and what the timing data shows

How to take thymosin alpha 1 has no consumer-facing answer, and anyone offering one is skipping the regulatory reality. In jurisdictions where thymalfasin is an approved medicine, it's supplied on prescription and given subcutaneously under clinical supervision. In a laboratory, the compound arrives as lyophilised powder and is handled as laboratory material.

Standard peptide handling practice stores lyophilised powder at -20C or colder, shielded from light and moisture, because the dry state is what preserves the sequence. Once reconstituted with sterile or bacteriostatic water, peptide solutions are generally held at 2 to 8C with freeze-thaw kept to a minimum, since repeated thermal stress degrades peptide integrity in ways that visual inspection will never reveal. Reconstitution math is simple documentation arithmetic: add 2mL of diluent to a 5mg vial and the solution measures 2.5mg per mL, so 10 units on a U-100 syringe equals 0.1mL, which equals 0.25mg. That's laboratory record-keeping, not a recommendation of any quantity.

How long does thymosin alpha 1 take to work? Two separate timescales are at play, and conflating them causes confusion. Pharmacokinetic reports from clinical studies describe a short plasma half-life measured in hours after subcutaneous administration. The immunological endpoints researchers actually track, lymphocyte subset counts and cytokine profiles, shift across weeks of repeated administration in published trials. Rapid clearance from plasma, slow change in the biological readout. We've seen more than one study design fail simply because the sampling window was built around the wrong one of those two numbers.

How much does thymosin alpha 1 cost across supply channels?

The table below compares the four routes this compound moves through, what the price actually buys in each, and what it leaves undocumented. Price signals are rough and vary widely by region, vial size and order volume.

Supply Channel	Typical Format	Rough Price Signal	What the Price Buys	Bottom Line
Pharmaceutical thymalfasin (approved markets outside the US)	Prescription vial, clinician-administered	Substantially higher per vial than research material; varies sharply by country	Regulatory approval in that jurisdiction, GMP manufacture, sterility and endotoxin release testing	The only route carrying approved-medicine status, and only where a regulator has granted it.
US compounding pharmacy	Historically compounded prescription vials	Largely moot; the channel is restricted	Nothing currently, given the FDA bulk-substance categorisation	Treat any active US compounding offer for this peptide with real scepticism.
Research-grade vial from a documented supplier	Lyophilised 5mg or 10mg vial, research use only	Typically roughly $40 to $150 per vial depending on size and specification	HPLC purity specification, mass-spec identity confirmation, batch certificate of analysis, cold-chain packing	Strongest transparency per dollar for laboratory work, provided the certificate is published and batch-matched.
Undocumented marketplace listing	Minimally labelled vial, no batch reference	Lowest headline price in the category	No verifiable identity, purity or peptide content data	Cheapest to buy, most expensive to interpret, because unknown content makes results uninterpretable.

What If: Research Sourcing Scenarios

What if two suppliers list the same 10mg vial at very different prices?

Request both certificates of analysis and compare peptide content, not vial weight. A supplier reporting 98% HPLC purity with mass-spec identity confirmation and a stated net peptide content is selling a measurably different product from one reporting only a label weight. The price gap frequently disappears once the cheaper vial's actual peptide mass is calculated, and the remaining difference buys analytical traceability.

What if the vial arrives warm after shipping?

Check the certificate for the stated storage specification and document the excursion in the batch record before anything else happens. Lyophilised peptide in the dry state tolerates short ambient exposure far better than reconstituted solution does, which is why suppliers ship powder rather than premixed material. Thermal damage to peptide structure isn't visible, so the receiving log is the only evidence a lab will ever have.

What if the powder looks like a thin film instead of a white cake?

A flattened film or a partially collapsed cake usually reflects lyophilisation cycle conditions or post-manufacture moisture exposure rather than a wrong compound. Appearance alone can't confirm identity or purity, which is why mass spectrometry exists. Match the batch number on the vial against the published certificate before drawing any conclusion about the material.

What if the certificate of analysis has no batch number on it?

Treat a generic certificate as marketing, not data. A certificate that isn't tied to the specific batch in hand tells you what some batch measured at some point, which is analytically worthless for reproducibility. Batch-matched documentation is the entire reason research-grade material commands more than anonymous marketplace pricing.

The unglamorous truth about peptide pricing

Let's be direct about this: below a certain price point, something in the documentation chain has been skipped, and it's almost never the peptide. It's the third-party mass spectrometry, the peptide content assay, or the cold-chain packing. A 28-residue sequence with an acetylated N-terminus has a floor cost driven by 28 coupling cycles and multiple HPLC passes, and chemistry doesn't negotiate. When a listing sits far under that floor, the rational conclusion isn't a better supplier. It's less testing, a lower net peptide fraction, or both.

Real Peptides supplies thymosin alpha 1 as research-grade material with batch documentation, alongside the related thymic-family compound TB-500, thymosin beta-4; batch certificates of analysis are published for review, the full catalog lists current vial formats, and shipping coverage is documented separately.

Ask how much does thymosin alpha 1 cost and you'll get a number back. Ask what's actually inside the vial and you'll get an education in peptide chemistry, because the two questions have almost nothing to do with each other. This molecule has been studied since the 1970s, approved as a medicine in some countries and never in others, and the dollar gap between a batch-documented vial and an anonymous one is usually small. What that gap buys is not potency. It's the ability to say, with evidence, what you actually measured.

References

Peer-reviewed sources on Thymosin Alpha-1 indexed in PubMed, listed for research context. Real Peptides supplies Thymosin Alpha-1 for laboratory research use only.

Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells. Cancer research, 2026. PMID 42295795. doi:10.1158/0008-5472.CAN-25-5547
The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets. OncoTargets and therapy, 2025. PMID 40955371. doi:10.2147/OTT.S527785
Aging and Thymosin Alpha-1. International journal of molecular sciences, 2025. PMID 41373628. doi:10.3390/ijms262311470
Interferon-α and thymosin-α1 plus tislelizumab enhance CD8(+) T cell cytotoxicity toward pancreatic ductal adenocarcinoma. iScience, 2025. PMID 40727936. doi:10.1016/j.isci.2025.113053
Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy. Cell reports. Medicine, 2024. PMID 39357524. doi:10.1016/j.xcrm.2024.101751
Enhanced Immunomodulatory Effects of Thymosin-Alpha-1 in Combination with Polyanionic Carbosilane Dendrimers against HCMV Infection. International journal of molecular sciences, 2024. PMID 38396631. doi:10.3390/ijms25041952
Thymosin α-1 in cancer therapy: Immunoregulation and potential applications. International immunopharmacology, 2023. PMID 36812669. doi:10.1016/j.intimp.2023.109744
Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era. International immunopharmacology, 2023. PMID 36871535. doi:10.1016/j.intimp.2023.109952

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Research-grade thymosin alpha 1 typically costs roughly $40 to $150 per vial, driven by vial size (usually 5mg or 10mg), documented purity specification and order volume. Pharmaceutical thymalfasin, approved in several countries outside the US, typically costs substantially more per vial. Compare stated peptide content rather than label weight.

Thymosin alpha 1 is a 28-amino-acid peptide that research suggests signals through Toll-like receptors TLR2 and TLR9 on dendritic cells and monocytes. That promotes dendritic cell maturation and a Th1-polarised cytokine profile involving interferon-gamma, IL-2 and IL-12, with reported effects on T-cell maturation and natural killer cell activity.

Published pharmacokinetic data report a short plasma half-life measured in hours after subcutaneous administration. The immunological endpoints researchers track, such as lymphocyte subset counts and cytokine shifts, change across weeks of repeated administration in clinical studies. Plasma clearance and biological readout run on genuinely different timescales.

In the research and clinical literature, thymosin alpha 1 has been studied in chronic hepatitis B and C, as a vaccine adjuvant in older populations affected by thymic involution, in sepsis and critical care, and in supportive oncology settings. Results vary by indication, and most clinical evidence comes from outside the United States.

Clinical literature from countries where thymalfasin is approved describes it as generally well tolerated, with injection-site reactions among the more commonly reported events. That record belongs to a GMP-manufactured, sterility-tested pharmaceutical product. Research-grade powder is not manufactured or released as a sterile injectable and carries no equivalent safety profile.

There is no consumer answer to this. Where thymalfasin is an approved medicine, it is prescribed and given subcutaneously under clinical supervision. Research-grade material is laboratory-use-only and is handled as such: stored lyophilised at -20C or colder, reconstituted with sterile water, and refrigerated at 2 to 8C afterwards.

Both sit in a similar research-grade price band, but chain length drives the difference. Thymosin alpha 1 is a 28-residue acetylated peptide, while TB-500 is a shorter fragment of thymosin beta-4, so synthesis cycles and purification passes differ. Vial size and purity specification usually matter more than the sequence itself.

The label figure is typically gross vial weight. Trifluoroacetate counterion left from reverse-phase HPLC purification, plus residual moisture from lyophilisation, contribute measurable mass. Suppliers that report net peptide content separately on the certificate of analysis let you calculate true cost per milligram of peptide rather than per milligram of powder.

Generally no. The FDA's review of bulk drug substances nominated for compounding placed thymosin alpha-1 in the category that significantly restricts use under section 503A, which effectively closed that route. The compound has no FDA approval for any indication, so US supply now moves as research-use-only material.

A usable certificate is batch-matched to the vial number and reports HPLC purity, mass-spectrometry identity confirmation against the expected molecular weight, and ideally net peptide content alongside gross weight. A generic certificate with no batch reference tells you nothing reproducible about the specific material in hand.

Lyophilised powder in the dry state tolerates short ambient exposure far better than reconstituted solution, which is why suppliers ship powder rather than premixed vials. Cold-chain packing still reduces risk. Any temperature excursion should be logged on receipt, because peptide degradation is not detectable by appearance.

It means the material is supplied for in vitro and laboratory investigation and is not manufactured, tested or sold as a drug product for human or veterinary consumption. It carries no FDA approval, no sterility release, and no endotoxin certification suitable for living subjects, regardless of purity specification.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA